ArticleOrthopedic reviews2025
Platelet-Rich Plasma Therapy in Treating Tendon Injuries of the Hand: A Narrative Review.
Article in Orthopedic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Synergistic Regenerative Strategies: Combining Polydeoxyribonucleotide with Biochemical and Physical Agents.International journal of molecular sciences · 2026Review
- Mechanism of Platelet-Rich Plasma in Promoting Diabetic Wound Healing via the PI3K/AKT Signaling Pathway to Regulate Collagen Synthesis and Angiogenesis.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich plasma (PRP) therapy has emerged as a biologically based approach to enhance tendon healing and functional recovery in hand and other musculoskeletal injuries. PRP is an autologous concentrate of platelets and growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), insulin-like growth factor (IGF), and vascular endothelial growth factor (VEGF), which modulate inflammation, stimulate tenocyte proliferation, promote collagen synthesis, and support angiogenesis. Preclinical studies demonstrate that PRP improves extracellular matrix remodeling, collagen fiber alignment, and biomechanical strength in injured tendons, with effects influenced by PRP formulation, leukocyte content, activation method, and timing of application. Clinical evidence in hand tendon injuries-particularly flexor tendon repair, chronic tendinopathies, and stenosing tenosynovitis-suggests that PRP is generally safe and may enhance tendon morphology, range of motion, pain relief, and return to function. However, results are heterogeneous, with some randomized trials showing limited short-term functional improvements compared to conventional treatments such as corticosteroids, hyaluronic acid, or percutaneous needle tenotomy. The variability in outcomes reflects differences in PRP preparation, injection protocols, injury chronicity, and study design. Beyond the hand, PRP has been applied to rotator cuff, lateral epicondylitis, plantar fasciitis, ligament injuries, and spinal surgery, with mixed results and some evidence of tissue-specific limitations. Current challenges include standardizing PRP formulations, optimizing dosing and delivery, and identifying patient- and injury-specific factors influencing response. Future research should prioritize multicenter, well-powered randomized trials with uniform outcome measures, long-term follow-up, robust safety monitoring, and exploration of combination therapies to clarify the therapeutic role of PRP and support evidence-based integration into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.